23
MAR
2017

NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors

Posted By :
Comments : Off
BETHESDA, Md., March 23, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that yesterday it closed on the $7.5 million financing it announced last Friday, March 17, 2017. The Company sold to several institutional investors securities totaling 28,843,692 shares, comprised of 18,843,692 common shares at $.26 per share,...
Read More
17
MAR
2017

NW BIO Announces Registered Direct Offering Of $7.5 Million

Posted By :
Comments : Off
BETHESDA, Md., March 17, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $7.5 million. In the transaction, the Company will sell approximately 28.8 million shares of common stock at a...
Read More
10
MAR
2017

NW Bio Reaches Agreement With Convertible Note Holders

Posted By :
Comments : Off
BETHESDA, MD, March 10, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors (“Whitebox”), holder of $11 million of NW Bio convertible senior notes. With these Notes otherwise...
Read More
06
FEB
2017

NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached

Posted By :
Comments : Off
Process Now Moving Forward Toward Data Lock   BETHESDA, Md., February 6, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Company’s Phase III trial of DCVax®-L for Glioblastoma multiforme (“GBM”) brain cancer (the “Trial”).  The Company announced that the partial...
Read More
18
JAN
2017

NW Bio Presenting At Phacilitate Immunotherapy World Conference

Posted By :
Comments : Off
BETHESDA, MD, January 18, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will present at the Phacilitate Immunotherapy World Conference on Thursday, January 19, 2017, at the Hyatt Regency Hotel in Miami, Florida. Dr....
Read More